Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil (Q44136534)

30 November 2017

Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil (English)

1 reference

30 November 2017

1 reference

Takeo Tedoriya

1

1 reference

30 November 2017

Anne M Keogh

2

1 reference

30 November 2017

Kengo Kusano

3

1 reference

30 November 2017

Elliott Savdie

4

1 reference

30 November 2017

Christopher Hayward

5

1 reference

30 November 2017

Phillip M Spratt

6

1 reference

30 November 2017

Michael Wilson

7

1 reference

30 November 2017

Peter S Macdonald

8

1 reference

30 November 2017

1 September 2002

1 reference

The Journal of Heart and Lung Transplantation

30 November 2017

1 reference

30 November 2017

21

1 reference

30 November 2017

9

1 reference

30 November 2017

976-982

1 reference

The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Treatment of end-stage renal failure after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Risks and costs of end-stage renal disease after heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

The long-term course of cyclosporine-associated chronic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Introduction of mycophenolate mofetil and cyclosporine withdrawal in heart transplant patients with progressive deteriorating renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Results of conversion from triple-drug to double-drug therapy in living related renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

The use of mycophenolate mofetil in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study G

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2802%2900422-9

7 January 2021

10.1016/S1053-2498(02)00422-9

Identifiers

DOI

1 reference

30 November 2017

1 reference